MX2009010047A - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX2009010047A
MX2009010047A MX2009010047A MX2009010047A MX2009010047A MX 2009010047 A MX2009010047 A MX 2009010047A MX 2009010047 A MX2009010047 A MX 2009010047A MX 2009010047 A MX2009010047 A MX 2009010047A MX 2009010047 A MX2009010047 A MX 2009010047A
Authority
MX
Mexico
Prior art keywords
chemical compounds
compositions
medicaments
compounds
dianilinopyrimidine
Prior art date
Application number
MX2009010047A
Other languages
English (en)
Inventor
Felix Deanda Jr
Paul Reid
David Harold Drewry
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2009010047A publication Critical patent/MX2009010047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención se refiere a derivados de dianilinopirimidina, a composiciones y medicamentos que los contienen, así como también a procesos para la preparación y uso de estos compuestos, composiciones y medicamentos. Estos derivados de dianilinopirimidina son útiles en el tratamiento de enfermedades asociadas con la actividad inapropiada de quinasa Wee1.
MX2009010047A 2007-03-20 2008-03-12 Compuestos quimicos. MX2009010047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89589907P 2007-03-20 2007-03-20
PCT/US2008/056622 WO2008115742A1 (en) 2007-03-20 2008-03-12 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2009010047A true MX2009010047A (es) 2009-12-04

Family

ID=39766348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010047A MX2009010047A (es) 2007-03-20 2008-03-12 Compuestos quimicos.

Country Status (11)

Country Link
US (1) US20100113445A1 (es)
EP (1) EP2136632A4 (es)
JP (1) JP2010522188A (es)
KR (1) KR20090121399A (es)
CN (1) CN101686675A (es)
AU (1) AU2008229151A1 (es)
BR (1) BRPI0809189A2 (es)
CA (1) CA2681250A1 (es)
EA (1) EA200901133A1 (es)
MX (1) MX2009010047A (es)
WO (1) WO2008115742A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010455A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102083800A (zh) 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010111702A (ja) * 2009-02-16 2010-05-20 Tetsuya Nishio 複素環化合物、その製造法および用途
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
EP3144298A1 (en) 2010-08-10 2017-03-22 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
RU2644151C2 (ru) 2010-11-01 2018-02-08 Селджен Авиломикс Рисерч, Инк. Гетероциклические соединения и их применение
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
US9370567B2 (en) 2010-11-16 2016-06-21 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors
WO2012151561A1 (en) 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
EP2825041B1 (en) 2012-03-15 2021-04-21 Celgene CAR LLC Solid forms of an epidermal growth factor receptor kinase inhibitor
RU2711077C9 (ru) 2012-03-15 2020-08-11 Селджен Кар Ллс Соли ингибитора киназы рецептора эпидермального фактора роста
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
CN109952303B (zh) * 2016-10-14 2022-10-21 林伯士拉克许米公司 Tyk2抑制剂及其用途
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
CN110831937A (zh) * 2017-05-02 2020-02-21 韩国化学研究院 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物
CN109206375B (zh) * 2017-07-07 2023-02-17 中国科学院上海药物研究所 一类5位环取代的具有苯甘氨醇类结构的2,4-二氨基嘧啶类化合物、其制备及用途
KR102440296B1 (ko) 2017-09-07 2022-09-06 한국화학연구원 피라졸기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
KR102383561B1 (ko) 2017-09-07 2022-04-06 한국화학연구원 테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
KR102063155B1 (ko) 2018-04-11 2020-01-08 한국과학기술연구원 우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체
SG11202110376XA (en) 2019-03-19 2021-10-28 Voronoi Inc Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component
BR112021026618A2 (pt) 2019-06-28 2022-06-07 Shanghai Pharmaceuticals Holding Co Ltd Composto de pirazolpirimidina, método de preparação do mesmo e aplicações do mesmo
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
AU2007257650A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha

Also Published As

Publication number Publication date
EP2136632A4 (en) 2011-01-19
US20100113445A1 (en) 2010-05-06
EA200901133A1 (ru) 2010-04-30
BRPI0809189A2 (pt) 2014-09-09
KR20090121399A (ko) 2009-11-25
CN101686675A (zh) 2010-03-31
AU2008229151A1 (en) 2008-09-25
JP2010522188A (ja) 2010-07-01
WO2008115742A1 (en) 2008-09-25
CA2681250A1 (en) 2008-09-25
EP2136632A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
MX2009010047A (es) Compuestos quimicos.
MX2009010045A (es) Compuestos quimicos.
EP1633740A4 (en) CHEMICAL COMPOUNDS
TW200738659A (en) Novel compounds
TW200801003A (en) Novel compounds
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2008067119A3 (en) Novel compounds
TW200639173A (en) Substituted pyrazolopyridines, compositions containing same, manufacturing process therefor and use thereof
TW200745084A (en) Novel compounds
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200738735A (en) Oxygen linked pyrimidine derivatives
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2004084813A3 (en) Chemical compounds
TW200745067A (en) Novel compounds
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
IN2012DN00785A (es)
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
PL1877367T3 (pl) Pochodne acetylenu
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200745122A (en) New compounds I
TW200833670A (en) Novel compounds 569
TW200738627A (en) Trialkylsilyl-indoles
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors